Radiochemotherapie
Studien
| Studie | RT | Chemotherapie | PFS | OS | Toxizität > 2° | Bemerkungen |
| RTOG 9610 (1) | 60 Gy hyperfraktioniert | 4x 5FU und Hydroxyurea | ? | 8,5 Monate | 85% | |
| RTOG 9911 (2) | 60 Gy hyperfraktioniert | 4x Cisplatin und Paclitaxel | 7,8 Monate | 12,1 Monate | 85% | |
| EXTREME (3) | ? | 6x Platin und 5FU | 3,3 Monate | 7,4 Monate | 76% | |
| ? | 6x Platin, 5FU, Ccetuximab | 5,6 Monate | 10,1 Monate | 82% | ||
| UPCI 06-093 | SBRT | 3x Cetuximab | 6,7 Monate | 10,0 Monate | 12% | |
| Lartigau (4) | SBRT | 5x Cetuximab | 7,1 Monate | 11,8 Monate | 30% |
Brachytherapie
Final report of RTOG 9610, a multi-institutional trial of re-irradiation and chemotherapy for unresectable recurrence squamous cell carcinoma of the head and neck.
Head Neck 2008;30:281-288.
2.) Langer CJ, Harris J, Horwitz EM, et al.:
Phase II study of low-dose paclitaxel and cisplatin in combination with split course concomitant twice daily reirradiation in Recurrent squamous cell carcinoma of the head and neck: Results of RT oncology group protocol 9911.
J Clin Oncol 2007;25:4800-4805.
3.) Vermorken JB, Mesia R, Rivera F, et al.:
Platinum-based chemotherapy plus cetuximab in head and neck cancer.
N Engl J Med 2008;359:1116-1127.
4.) Lartigau EF, Tresch E, Thariat J, et al.:
Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.
Radiother Oncol 2013;109:281-285.
5.) Vargo JA, et al.:
A Prospective Phase 2 Trial of Reirradiation With Stereotactic Body Radiation Therapy Plus Cetuximab in Patients With Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck.
Int J Radiation Oncol Biol Phys 2015; 91:480-488. http://dx.doi.org/10.1016/j.ijrobp.2014.11.023
6.) Strnad V, et al.:
Reirradiation for recurrent head and neck cancer with salvage interstitial pulsed-dose-rate brachytherapy. Long-term results.
Strahlenther Onkol 2015;191:495–500. DOI 10.1007/s00066-014-0809-8
